Cytokine sustained delivery for cancer therapy; special focus on stem cell- and biomaterial- based delivery methods

• Published in: Pathology, research and practice research and practice, 2023-07, Vol.247, p.154528-154528, Article 154528
• Main Authors: Mehralizadeh, Hossein, Nazari, Ahmad, Oruji, Farshid, Roostaie, Minoo, Hosseininozari, Ghazaleh, Yazdani, Omid, Esbati, Romina, Roudini, Kamran
• Format: Article
• Language: English
• Subjects: Biocompatible Materials; Biomaterial; Cytokine; Cytokines; Humans; Immunotherapy; Mesenchymal Stem Cells; Neoplasms - therapy; Stem cell; Tumor
• ISSN: 0344-0338; 1618-0631
• DOI: 10.1016/j.prp.2023.154528

As immune regulators, cytokines serve critical role as signaling molecules in response to danger, tissue damage, or injury. Importantly, due to their vital role in immunological surveillance, cytokine therapy has become a promising therapeutics for cancer therapy. Cytokines have, however, been used only in certain clinical settings. Two key characteristics of cytokines contribute to this clinical translational challenge: first, they are highly pleiotropic, and second, in healthy physiology, they are typically secreted and act very locally in tissues. Systemic administration of the cytokines can consequently result in serious side effects. Thus, scientists have sought various strategies to circumvent theses hurdles. Recent in vivo reports signify that cytokine delivery platforms can increase their safety and therapeutic efficacy in tumor xenografts. Meanwhile, cytokine delivery using multipotent stem cells, in particular mesenchymal stem/stromal cells (MSCs), and also a diversity of particles and biomaterials has demonstrated greater capability in this regards. Herein, we take a glimpse into the recent advances in cytokine sustained delivery using stem cells and also biomaterials to ease safe and effective treatments of a myriad of human tumors.